Turn Therapeutics Inc. TTRX

Full chart Compare

Set alert

9.92 USD +0.13 (+1.33%)

At closeNov 10, 2026, 4:00 PM EST

9.92 0.00 0.00%

After hours · Nov 10, 4:00 PM ET

9.52 Day range 10.22

2.57 52-week range 16.45

YTD: +151.78%
1 year: +140.19%

News

1 day ago gurufocus.com Turn Therapeutics Provides Corporate Updates and Reports Third Quarter 2026 Financial Results Turn Therapeutics Inc. (Nasdaq: TTRX), a clinical-stage biotechnology company developing targeted, non-systemic therapies for inflammatory and infectious skin d
1 day ago benzinga.com Turn Therapeutics Q3 EPS $(0.21) Misses $(0.09) Estimate Turn Therapeutics (NASDAQ:TTRX) reported quarterly losses of $(0.21) per share which missed the analyst consensus estimate of $(0.09) by 162.5 percent. This is a 200 percent decrease over losses of…
1 day ago businesswire.com Turn Therapeutics Provides Corporate Updates and Reports Third Quarter 2026 Financial Results WESTLAKE VILLAGE, Calif.--(BUSINESS WIRE)--Turn Therapeutics Inc. (Nasdaq: TTRX), a clinical-stage biotechnology company developing targeted, non-systemic therapies for inflammatory and infectious…
5 days ago businesswire.com Turn Therapeutics' GX-03 Earns “Developmental Immunology Solution of the Year” in 2026 BioTech Breakthrough Awards Program WESTLAKE VILLAGE, Calif.--(BUSINESS WIRE)--Turn Therapeutics Inc. (Nasdaq: TTRX), a clinical-stage biotechnology company developing targeted, non-systemic therapies for inflammatory skin diseases,…
2 weeks ago benzinga.com This Tesla Analyst Turns Bullish; Here Are Top 5 Upgrades For Monday Analysts upgraded SAFE, CNOB, LMT and more.
2 weeks ago benzinga.com This Allegion Analyst Turns Bullish; Here Are Top 5 Upgrades For Friday Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings…
2 weeks ago benzinga.com WBB Securities Upgrades Turn Therapeutics to Hold, Maintains Price Target to $10 WBB Securities analyst Karen Sterling upgrades Turn Therapeutics (NASDAQ:TTRX) from Sell to Hold and maintains the price target from $10 to $10.